No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 9
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Psyence Biomedical Ltd. (PBM) stock was $5.02 as of Oct 6, 2026, 4:00 PM EDT, down 1.18% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -73.5%
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin.
Biotechnology · Toronto, ON
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PBM | $95,475 | $5.02 | -1.18% | -73.54% | N/A | N/A | N/A |
| 2SLXN | $110,112 | $0.26 | -1.20% | -99.31% | N/A | N/A | vs PBM |
| 3PRFX | $70,884 | $0.88 | -0.46% | -87.06% | -74.50% | N/A | vs PBM |
| 4AKAN | $61,172 | $1.89 | -1.05% | -96.82% | N/A | N/A | vs PBM |
| 5ZCMD | $30,389 | $1.75 | -8.38% | -99.89% | -84.76% | N/A | vs PBM |
| 6MNDR | $29,771 | $1.21 | -5.51% | -99.03% | N/A | N/A | vs PBM |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$5.02
High
N/A
